Raghunathan R, et al. - The impact of fluorodeoxyglucose positron-emission tomography (PET) staging and age-adjusted comorbidities (AACs) was examined by researchers on the management and survival of non–small-cell lung cancer (NSCLC) in individuals who underwent initial PET scan and received care at the Ann Arbor Veterans Hospital between 2005 and 2010. As per the findings, PET scans resulted in upstaging in 15% in CS I-III NSCLC. Yielded data depicted that age-adjusted comorbidities (AACs) scores dictated therapy decisions and outcomes more than PET staging. Veterans presented with lower 5-year survival rates (26.3%, 15.8%/13.4%) compared with 53% and 27% in age/sex/time-period matched SEER data for stage I-II/III NSCLC.